BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
Camille KockerolsPeter J M ValkNicole M A BlijlevensJan J CornelissenAvinash G DinmohamedInge GeelenMels HoogendoornJeroen J W M JanssenLaura G M DaenenBert A van der ReijdenPeter E WesterweelPublished in: European journal of haematology (2023)
We recommend BCR::ABL1 KD mutation testing in particular in the context of primary or secondary resistance. IC50-values can direct the TKI choice for CML patients, but clinical efficacy can be seen despite adverse in vitro resistance.